

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15665-007US1	Application No. 10/563,389
		Applicant Caesson Welsh et al.	
		Filing Date February 15, 2007	Group Art Unit 1614

**Information Disclosure Statement**  
**by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
------------------	-----------	-----------------	------------------	----------	-------	----------	----------------------------

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	1.	Borza and Morgan, "Histidine-Proline-rich Glycoprotein as a Plasma pH Sensor," <u>J. Biol. Chem.</u> , 1998, 273(10):5493-5499
	2.	Borza and Morgan, "Acceleration of Plasminogen Activation by Tissue Plasminogen Activator on Surface-bound Histidine-proline-rich Glycoprotein," <u>J. Biol. Chem.</u> , 1997, 272(8):5718-5726
	3.	Brown and Parish, "Histidine-Rich Glycoprotein and Platelet Factor 4 Mask Heparan Sulfate Proteoglycans Recognized by Acidic and Basic Fibroblast Growth Factor," <u>Biochem.</u> , 1994, 33:13918-13927
	4.	Carmeliet and Jain, "Angiogenesis in cancer and other diseases," <u>Nature</u> , 2000, 407:249-257
	5.	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <u>Nature Med.</u> , 1995, 1(1):27-31
	6.	Gorgani et al., "Histidine-Rich Glycoprotein Binds to Human IgG and C1q and Inhibits the Formation of Insoluble Immune Complexes," <u>Biochem.</u> , 1997, 36:6653-6662
	7.	Gorgani et al., "Histidine-Rich Glycoprotein Binds to DNA and FcγRI and Potentiates the Ingestion of Apoptotic Cells by Macrophages," <u>J. Immunol.</u> , 2002, 169:4745-4751
	8.	Gura, "Cancer Models: Systems for Identifying New Drugs Are Often Faulty," <u>Science</u> , 1997, 278:1041-1042
	9.	Hawighorst et al., "Activation of the Tie2 Receptor by Angiopoietin-1 Enhances Tumor Vessel Maturation and Impairs Squamous Cell Carcinoma Growth," <u>Am. J. Pathol.</u> , 2002, 160(4):1381-1392
	10.	Kerbel, "Tumor angiogenesis: past, present and the near future," <u>Carcinogenesis</u> , 2000, 21(3):505-515
	11.	Koide et al., "The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III," <u>FEBS</u> , 1986, 194(2):242-244
	12.	Kluszynski et al., "Zinc as a Cofactor for Heparin Neutralization by Histidine-rich Glycoprotein," <u>J. Biol. Chem.</u> , 1997, 272(21):13541-13547
	13.	Lamb-Wharton and Morgan, "Induction of T-Lymphocyte Adhesion by Histidine-Proline-Rich Glycoprotein and Concanavalin A," <u>Cell. Immunol.</u> , 1993, 152:544-555
	14.	Lijnen et al., "Heparin Binding Properties of Human Histidine-rich Glycoprotein. Mechanism and Role in the Neutralization of Heparin in Plasma," <u>J. Biol. Chem.</u> , 1983, 258(6):3803-3808
	15.	Olsen et al., "Histidine-rich glycoprotein binding to T-cell lines and its effect on T-cell substratum adhesion is strongly potentiated by zinc," <u>Immunology</u> , 1996, 88:198-206
	16.	Peterson et al., "Histidine-rich Glycoprotein Modulation of the Anticoagulant Activity of Heparin," <u>J. Biol. Chem.</u> , 1987, 262(16):7567-7574

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15665-007US1	Application No. 10/563,389
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Claesson Welsh et al.	
		Filing Date February 15, 2007	Group Art Unit 1614
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	17.	Simon et al., "Peptoids: A modular approach to drug discovery," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, 89:9367-9371
	18.	Zhang et al., "Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5," <u>FASEB J.</u> , 2000, 14:2589-2600
	19.	Wassberg et al., "Inhibition of Angiogenesis Induces Chromaffin Differentiation and Apoptosis in Neuroblastoma," <u>Am. J. Pathol.</u> , 1999, 154(2):395-403

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	